<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01987128</url>
  </required_header>
  <id_info>
    <org_study_id>IOGPGC04-13</org_study_id>
    <nct_id>NCT01987128</nct_id>
  </id_info>
  <brief_title>Popliteal Sciatic Nerve Block: Intraneural or Extraneural?</brief_title>
  <official_title>Blocco Del Nervo Sciatico al Poplite, Intraneurale o Extraneurale? Confronto Prospettico, Randomizzato in Cieco Tra la modalit√† di Iniezione di Anestetico Locale Per il Blocco Eco Guidato Del Nervo Sciatico al Poplite Nella Chirurgia Dell'Alluce Valgo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ASST Gaetano Pini-CTO</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ASST Gaetano Pini-CTO</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of this study is to demonstrate the advantages of intraneural injection over extraneural
      injection in terms of onset and duration on peripheral block. In addition we will evaluate
      the frequency of possible adverse effects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>onset time</measure>
    <time_frame>every 2 minutes for a maximum of 30 minutes</time_frame>
    <description>Pinprick test evaluation on sciatic nerve territory:
With a 22G needle the blinded operator will assess sensitiveness to puncture and then assign a score every 2 minutes for 30 minutes. A score of 0 will describe no sensation to puncture, on the other hand a score of 1 will be assigned if sensation to puncture is still present.
Evaluation of motor blockade:
Plantar and dorsal flexion of the foot will be evaluated for motor blockade of sciatic nerve. A score of 1 will be assigned if foot movement is conserved, 2 if is impaired and 3 when disappears.
Onset time is described as the time at which pinprick score turns to 0 and motor blockade score turns to 3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>success rate in each group</measure>
    <time_frame>at 30 minutes</time_frame>
    <description>Success rate is described as the percentage of subjects with an onset time within 30 minutes in a group among all subjects treated in that group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nerve injuries</measure>
    <time_frame>1, 5 weeks and at 6 months after surgery</time_frame>
    <description>Neurophysiological and clinic evaluation will be assessed either with clinical examination and electrophysiological tests by a neurophysiologist eventually evidencing any movement impairment or dysesthesia in the sciatic territory.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Hallux Valgus</condition>
  <arm_group>
    <arm_group_label>Intraneural injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients in the arm will receive a single intraneural injection of 12 ml Ropivacaine 1% BBraun, Germany, in the sciatic nerve under echographic guidance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>extraneural injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients in the arm will receive a single extraneural injection of 12 ml Ropivacaine 1% BBraun, Germany, around the sciatic nerve under echographic guidance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intraneural injection</intervention_name>
    <description>BBraun Ropivacaine 1% 12ml injection divided in each sciatic components under echographic guidance with a PAJUNK SonoPlex 22G needle.</description>
    <arm_group_label>Intraneural injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Extraneural injection</intervention_name>
    <description>BBraun Ropivacaine 1% 12ml extraneural injection around sciatic nerve under echographic guidance with a PAJUNK SonoPlex 22G needle.</description>
    <arm_group_label>extraneural injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <arm_group_label>Intraneural injection</arm_group_label>
    <arm_group_label>extraneural injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PAJUNK SonoPlex 22G needle.</intervention_name>
    <arm_group_label>Intraneural injection</arm_group_label>
    <arm_group_label>extraneural injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA I-II

        Exclusion Criteria:

          -  Neurological diseases

          -  Diabetes

          -  Allergies to used drugs

          -  Chronic pain in treatment

          -  Electrophysiological alterations at time zero analysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gianluca Cappelleri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ASST Gaetano Pini-CTO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Ortopedico G. Pini</name>
      <address>
        <city>Milan</city>
        <state>Milano</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2013</study_first_submitted>
  <study_first_submitted_qc>November 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2013</study_first_posted>
  <last_update_submitted>February 26, 2015</last_update_submitted>
  <last_update_submitted_qc>February 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>ASST Gaetano Pini-CTO</investigator_affiliation>
    <investigator_full_name>Gianluca Cappelleri</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hallux Valgus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

